Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL595004 | 0.93 | LMNA (0.46) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL11585200 | 0.91 | LMNA (0.44) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL8679740 | 0.89 | LMNA (0.40) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Demannose SCHEMBL3935915 | 0.81 | LMNA (0.35) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL6658970 | 0.81 | ALDH1A1 (0.35) | LMNAL3MBTL1PDE4ATDP1KDM4E | |
| Propylene Glycol SCHEMBL7930115 | 0.78 | TDP1 (0.48) | LMNATDP1ALDH1A1HSD17B10PIN1 | |
| Alcohol SCHEMBL2046416 | 0.78 | ALDH1A1 (0.46) | LMNAALDH1A1HSD17B10PIN1ALOX15 | |
| SCHEMBL471892 | 0.78 | ALDH1A1 (0.50) | LMNAALDH1A1HSD17B10PIN1ALOX15 | |
| SCHEMBL22598 | 0.78 | — | — | |
| SCHEMBL344175 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354453-B2 | Bupropion hydrobromide and therapeutic applications | VALEANT INTERNATIONAL BERMUDA (BM) | 2013-01-15 | — | — | US | disclosed |
| US-20100104639-A1 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104639-A1 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS | GABBR1, SLC6A2, GABBR2 | LMNA 3064/4885L3MBTL1 2077/4885PDE4A 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.